18

2026

-

06

Microread Fragile X Kit Passes Russian Quality System Inspection


From June 16 to 18, 2026, an official inspection team from Russia’s Federal Service for Surveillance in Healthcare (Roszdravnadzor, RZN) visited Microread Genetics to conduct a three-day, on-site quality system inspection of an overseas manufacturer, focusing on the company’s core product, the Fragile X Syndrome FMR1 Gene Detection Kit. With its standardized system for international regulatory compliance, Microread passed the inspection on its first attempt with no major nonconformities, accelerating its plans to bring the product to Russia and the Eurasian Economic Union (EAEU).

The inspection was conducted against ISO 13485 international quality management system requirements and Russia’s medical device market entry standards. The team rigorously assessed six areas: traceability of product research and development; production controls in the Class 100,000 cleanroom for molecular diagnostics reagents; end-to-end quality controls; stability validation for cross-border distribution; Russian-language regulatory documentation; and supply chain quality controls. The review covered the full documentation chain, including manufacturing processes, batch controls, risk management and overseas regulatory filings. The team also verified the site’s capabilities across the entire product realization process, including cold-chain storage and finished-product release.

Opening meeting of the on-site quality system inspection

Throughout the inspection, Microread’s R&D, production, quality, regulatory affairs, logistics and warehousing, and technical service teams worked closely together to answer questions and provide documentation. The inspection team gave strong recognition to three core strengths:

  • Microread’s proprietary core technology for Fragile X testing meets screening needs in populations across the Commonwealth of Independent States (CIS), with testing accuracy meeting Russian requirements for clinical market entry.
  • The company has established an integrated quality management system for domestic and international operations, with closed-loop processes and traceable records that fully meet Russia’s stringent inspection requirements for overseas in vitro diagnostic (IVD) manufacturers.
  • Its well-established coordination across R&D, production and quality supports reliable supply at scale and the fulfillment of cross-border orders.

On-site inspection of the reagent production cleanroom

Passing the Russian on-site inspection is a key milestone toward obtaining the product’s official Russian registration certificate and carries important strategic significance. It opens a pathway to EAEU market access for Microread’s Fragile X testing product, helps address a gap in the Russian market for Chinese-developed testing reagents for rare disorders in reproductive genetics, and broadens opportunities for overseas commercialization. It also demonstrates that the company’s quality system and R&D and manufacturing capabilities meet leading international regulatory standards, setting a benchmark for regulatory compliance among Chinese IVD companies entering CIS markets.

Responding to inspectors’ questions on site

Next, Microread Genetics will steadily advance the remaining registration procedures, continue to improve its quality management system, and deepen its expertise in precision diagnostics for reproductive genetics. The company will also continue to expand the global presence of its innovative diagnostic products, supporting the international growth of Chinese IVD brands.

Previous page